Cargando…

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial

BACKGROUND: The prognosis for advanced hepatocellular carcinoma (HCC) remains clinically unsatisfying. Apatinib has proven to be a very effective treatment for advanced HCC in our previous retrospective study. Our aim in this study was to evaluate the efficacy, safety, and toxicity of apatinib in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Zhenyu, Zhu, Keyun, Yang, Xuejiao, Chen, Ping, Zhang, Wei, Cui, Yunlong, Zhu, Xiaolin, Song, Tianqiang, Li, Qiang, Li, Huikai, Zhang, Ti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576000/ https://www.ncbi.nlm.nih.gov/pubmed/33145266 http://dx.doi.org/10.21037/atm-20-2990

Ejemplares similares

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
por: Wang, Huaqi, et al.
Publicado: (2021)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
por: Gu, Xiaoying, et al.
Publicado: (2022)

Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma
por: Sun, Lin, et al.
Publicado: (2017)

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(−)CD45(+) cells during hepatocellular carcinoma progression
por: Zhu, Xiaolin, et al.
Publicado: (2017)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2020)

High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2021)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
por: Gan, Leijuan, et al.
Publicado: (2023)

MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways
por: Fang, Feng, et al.
Publicado: (2017)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
por: Wang, Hongzhi, et al.
Publicado: (2022)

Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol
por: Huang, Jun Tao, et al.
Publicado: (2023)

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial
por: Sun, Hui-Chuan, et al.
Publicado: (2020)

Apatinib in Combination with S‐1 as First‐Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single‐Arm, Phase II Trial
por: Zhou, Na, et al.
Publicado: (2020)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
por: Mao, Jinzhu, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
por: Zhu, Guopei, et al.
Publicado: (2021)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway
por: Zhang, Hua, et al.
Publicado: (2018)

Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial
por: Teng, Fei, et al.
Publicado: (2022)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Hepatocellular carcinoma successfully treated with ALPPS and apatinib: A case report
por: Liu, Ling, et al.
Publicado: (2019)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
por: Xu, Yanjun, et al.
Publicado: (2019)

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma
por: Yu, Ge, et al.
Publicado: (2022)

Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study
por: Chen, Runzhi, et al.
Publicado: (2022)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report
por: Zhu, Hong, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study
por: Ren, Dengfeng, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mt8n9fkrhno1a9vah3nbg57qcp